Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline.
Authors:
Journal: PloS one
Publication Type: Journal Article
Date: 2020
DOI: PMC7259639
ID: 32469871
Abstract
Alzheimer's disease (AD) pathology precedes symptoms and its detection can identify at-risk individuals who may benefit from early treatment. Since the retinal nerve fiber layer (RNFL) is depleted in established AD, we tested whether its thickness can predict whether cognitively healthy (CH) individuals have a normal or pathological cerebrospinal fluid (CSF) Aß42 (A) and tau (T) ratio.
Chemical List
- Amyloid beta-Peptides|||Biomarkers|||tau Proteins
Reference List
- 2019 Alzheimer's disease facts and figures. Alzheimers Dement. 2019;15(3):321–87.|||Batsch NL, Mittelman MS, eds. World Alzheimer Report 2012: Overcoming the Stigma of Dementia. Ldon: Alzheimer’s Disease International; 2012:75.|||Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med 2011;3:77sr1.|||Uhlmann RF, Larson EB, Koepsell TD, Rees TS, Duckert LG. Visual impairment and cognitive dysfunction in Alzheimer’s disease. J Gen Intern Med. 1991;6:126–32.|||Guo L, Salt TE, Maass A, Luong V, Moss SE, Fitzke FW, et al. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest Ophthalmol Vis Sci 2006; 47: 626–33.|||Javaid FZ, Brenton J, Guo L, Cordeiro MF. Visual and Ocular Manifestations of Alzheimer's Disease and Their Use as Biomarkers for Diagnosis and Progression. Front Neurol. 2016;7:55.|||Sadun AA, Johnson BM, Miao M. Axon caliber populations in the human optic nerve: change with age and disease. Int Neuro-Oph Society 1986:5–20.|||Zanetti O, Solerte SB, Cantoni F. Life expectancy in Alzheimer's disease (AD). Arch Gerontol Geriatr. 2009;49 Suppl 1:237–43.|||Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer’s disease. Surv Ophthalmol 1989;34:31–43.|||Salamone G, Di lorenzo C, Mosti S, et al. Color discrimination performance in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;27(6):501–7.|||Tzekov R, Mullan M. Vision function abnormalities in Alzheimer disease. Surv Ophthalmol. 2014;59(4):414–33.|||Dugger BN, Tu M, Murray ME, Dickson DW. Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive supranuclear palsy. Neurosci Lett. 2011;491(2):122–6.|||The Retina In: Purves D, et al., eds. Neuroscience. 2nd ed Chapters 11 and 12. Sunderland (MA): Sinauer Associates; 2001.|||Byerly MS, Blackshaw S. Vertebrate retina and hypothalamus development. Wiley Interdiscip Rev Syst Biol Med. 2009;1 (3):380–9.|||Trost A, Lange S, Schroedl F, et al. Brain and Retinal Pericytes: Origin, Function and Role. Front Cell Neurosci. 2016;10:20.|||Thomson KL, Yeo JM, Waddell B, Cameron JR, Pal S. A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimers Dement (Amst). 2015;1(2):136–43.|||Sadun A, Borchert M, DeVita E et al. Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol 1987; (104):113–20.|||Liu D, Zhang L, Li Z, et al. Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer’s disease. BMC Neurology 2015; 15:14.|||Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer’s disease. N Engl J Med 1986;315(8):485–7.|||La Morgia C, Ross-Cisneros FN, Koronyo Y, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016;79(1):90–109.|||Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer’s: exploring disease in the retina. Acta Neuropathol. 2016;132 (6):767–87.|||Alexandrov PN, Pogue A, Bhattacharjee S, Lukiw WJ. Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer’s disease. Neuroreport. 2011;22 (12):623–7.|||Koronyo-hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011;54 Suppl 1:S204–17.|||Schön C, Hoffmann NA, Ochs SM, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS ONE. 2012;7(12):e53547.|||Garcia-Martin E, Rodriguez-Mena D, Herrero R, et al. Neuro-ophthalmologic evaluation, quality of life, and functional disability in patients with MS. Neurology 2013; 81: 76–83.|||Garcia-Martin E, Bambo MP, Marques ML. Ganglion cell layer measurements correlate with disease severity in patients with Alzheimer’s disease. Acta Ophthalmologica 2016; 454–9.|||Liu D, Zhang L, Li Z, et al. Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer’s disease. BMC Neurology 2015; 15:14.|||Chan VTT, Sun Z, Tang S, et al. Spectral domain-optical coherence tomography measurements in Alzheimer’s disease: a systematic review and meta-analysis. Ophthalmology 2018; S0161-6420(18)30258-6.|||Coppola G, Renzo AD, Ziccardi L et al. Optical Coherence Tomography in Alzheimer’s Disease: A Meta-Analysis. PLOS ONE 2015; 10 (8).|||Shen Y, Shi Z, Jia R, Zhu Y, Cheng Y, Feng W, et al. The attenuation of retinal nerve fiber layer thickness and cognitive deterioration. Front Cell Neurosci 2013; 7: 142.|||Shen Y, Liu L, Cheng Y, Feng W, Shi Z, Zhu Y et al. Retinal nerve fiber layer thickness is associated with episodic memory deficit in mild cognitive impairment patients. Curr Alzheimer Res 2014; 11: 259–66.|||Shi Z, Wu Y, Wang M, Cao J, Feng W, Cheng Y et al. Greater attenuation of retinal nerve fiber layer thickness in Alzheimer's disease patients. J Alzheimers Dis. 2014; 40: 277–83.|||Kromer R, Serbecic N, Hausner L, Froelich L, Aboul-Enein F, Beutelspacher SC. Detection of Retinal Nerve Fiber Layer Defects in Alzheimer's Disease Using SD-OCT. Front Psychiatry 2014; 5: 22.|||Ascaso F, Cruz N, Modrego P, Lopez-Anton R, Santabárbara J, Pascual LF et al. Retinal alterations in mild cognitive impairment and Alzheimer's disease: an optical coherence tomography study. J Neurol 2014; 261: 1522–30.|||Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 2013; 9: 54–8.|||Small GW, Siddarth P, Kepe V, Ercoli LM, Burggren AC, et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 2012; 69: 215–22.|||Harrington MG, Chiang J, Pogoda JM, et al. Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study. PLoS ONE. 2013;8(11):e79378.|||Pillai JA, Cummings JL. Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am 2013; 97: 439–57.|||Mwanza JC, Oakley JD, Budenz DL, Chang RT, Knight OJ, Feuer WJ. Macular ganglion cell-inner plexiform layer: automated detection and thickness reproducibility with spectral domain-optical coherence tomography in glaucoma. Invest Ophthalmol Vis Sci 2011;52(11):8323–9.|||Hu J, Gottlieb CB, Barajas DJ, Barnett CJ, Schoenholz T, Sadda SR. Improved repeatability of retinal thickness measurements using line-scan ophthalmoscope image-based retinal tracking. Ophthalmic Surg Lasers Imaging Retina. 2015;46(3):310–4.|||Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid [1]-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382–9.|||Chiasseu M, Alarcon-martinez L, Belforte N, et al. Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease. Mol Neurodegener. 2017;12(1):58.|||Parisi V, Restuccia R, Fattapposta F, et al. Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol 2001; 112: 1860–1867.|||Iseri PK, Altinas O, Tokay T, et al. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 2006; 26:18–24.|||Berisha F, Feke GT, Trempe CL, et al. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 2007;48: 2285–2289.|||Paquet C, Boissonnot M, Roger F, et al. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2007; 420: 97–99.|||Lu Y, Li Z, Zhang X, et al. Retinal nerve fiber layer structure abnormalities in early Alzheimer's disease: evidence in optical coherence tomography. Neurosci Lett 2010; 480: 69–72.|||Kirbas S, Turkyilmaz K, Anlar O, et al. Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neuroophthalmol 2013; 33:58–61.|||Marziani E, Pomati S, Ramolfo P, et al. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer's disease using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2013; 54: 5953–5958.|||Oktem EO, Derle E, Kibaroglu S, et al. The relationship between the degree of cognitive impairment and retinal nerve fiber layer thickness. Neurol Sci 2015;36: 1141–1146.|||Cheung CY, Ong YT, Hilal S, et al. Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2015; 45: 45–56.|||Kesler A, Vakhapova V, Korczyn AD, et al. Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg 2011; 113: 523–526.|||Cunha LP, Lopes LC, Costa-cunha LV, et al. Macular Thickness Measurements with Frequency Domain-OCT for Quantification of Retinal Neural Loss and its Correlation with Cognitive Impairment in Alzheimer's Disease. PLoS ONE. 2016;11(4):e0153830.|||Asanad S, Ross-cisneros FN, Nassisi M, Barron E, Karanjia R, Sadun AA. The Retina in Alzheimer's Disease: Histomorphometric Analysis of an Ophthalmologic Biomarker. Invest Ophthalmol Vis Sci. 2019;60(5):1491–1500.|||Sadun AA, Borchert M, DeVita E, et al. Assessment of visual impairment in patients with Alzheimer’s disease. Am J Ophthalmol. 1987;104:113–120.|||Remington LAR. Clinical Anatomy and Physiology of the Visual System. 3rd ed Oxford, UK: Butter Worth Heinemann; 2012:61–92.|||Santos CY, Johnson LN, Sinoff SE, Festa EK, Heindel WC, Snyder PJ. Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease. Alzheimers Dement (Amst). 2018;10:196–209.|||Gao L, Liu Y, Li X, Bai Q, Liu P. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. Arch Gerontol Geriatr 2015;60:162–7.|||Wu Y, Wang XN, Wang N, et al. Regularity changes of the retinal nerve fiber layer and macular ganglion cell complex in patients with the amnestic mild cognitive impairment. Int J Neurosci 2018;128:849–53.|||Choi SH, Park SJ, Kim NR. Macular ganglion cell-inner plexiform layer thickness is associated with clinical progression in mild cognitive impairment and Alzheimers disease. PLoS One 2016;11:e0162202.|||Almeida ALM, Pires LA, Figueiredo EA, et al. Correlation between cognitive impairment and retinal neural loss assessed by swept-source optical coherence tomography in patients with mild cognitive impairment. Alzheimers Dement (Amst). 2019;11:659–669.|||Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, et al. Retinal nerve fiber layer thinning in Alzheimer’s disease: a case-control study in comparison to normal aging, Parkinson’s disease, and non-Alzheimer’s dementia. Am J Alzheimers Dis Other Demen 2016;31:430–6.|||Feke GT, Hyman BT, Stern RA, Pasquale LR. Retinal blood flow in mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement (Amst) 2015;1:144–51.|||Lad EM, Mukherjee D, Stinnett SS, et al. Evaluation of inner retinal layers as biomarkers in mild cognitive impairment to moderate Alzheimer’s disease. PLoS One. 2018;13:e0192646.|||Leite MT, Rao HL, Weinreb RN, et al. Agreement among spectral domain optical coherence tomography instruments for assessing retinal nerve fiber layer thickness. Am J Ophthalmol. 2011;151:85e92.e1.|||Spencer RJ, Wendell CR, Giggey PP, et al. Psychometric limitations of the Mini-Mental State Examination among nondemented older adults: an evaluation of neurocognitive and magnetic resonance imaging correlates. Exp Aging Res 2013;39:382–97.|||Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594e1599.|||Van de kreeke JA, Nguyen HT, Den haan J, et al. Retinal layer thickness in preclinical Alzheimer's disease. Acta Ophthalmol 2019;97(8):798–804.|||Alber J, Goldfarb D, Thompson LI, et al. Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward. Alzheimers Dement 2020;16(1):229–243.